Halozyme Therapeutics | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amarin USD 201.55M 28.99M 2024-09
Amgen USD 23.1B 2.79B 2024-12
Baxter International USD 6.51B 311M 2024-12
Cytokinetics USD 179.67M 69.86M 2024-12
DBV Technologies USD 30.91M 3.53M 2024-09
Eli Lilly USD 28.38B 3.7B 2024-12
Halozyme Therapeutics USD 139.1M 30.28M 2024-12
Indivior 962M 50M 2024-09
Intra Cellular Therapies USD 205.7M 39.59M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
MannKind USD 81.84M 9.74M 2024-12
Pfizer USD 43B 216M 2024-12
United Therapeutics USD 738.1M 135.3M 2024-12



Halozyme Therapeutics Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.